Dermatology

Results from the Phase III ICONIC-LEAD trial reveal that JNJ-2113 (icotrokinra, Johnson & Johnson, New Jersey), an oral peptide targeting the IL-23 receptor, demonstrated improvements in skin clearance among patients with moderate to severe plaque psoriasis.

A significant risk associated with immune checkpoint inhibitors (ICIs), a class of cancer therapies, has been identified in a new study.

A recent study has found a significant association between fine particulate air pollution (PM2.5) and eczema, highlighting a potential environmental driver of the skin condition among American adults.

New evidence highlights the potential of laser hair removal and intense pulsed light (IPL) therapy in reducing lesion count and flare-ups for patients with hidradenitis suppurativa (HS).

Wide local excision and Mohs surgery are the leading treatments for melanoma patients with positive tumor margins, according to findings presented at the American Society for Dermatologic Surgery Annual Meeting.

Nutritional and microbial strategies are emerging as pivotal in treating skin conditions such as acne, alopecia, and atopic dermatitis.

Nearly half of patients with metastatic melanoma treated with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab have survived cancer-free, underscoring the impact of immunotherapy in advanced melanoma.

A major randomized clinical trial has demonstrated that home-based narrowband UV-B phototherapy is as effective as office-based treatment for patients with plaque or guttate psoriasis.